Notably, it was also observed that AML samples containing WT FLT3 were also sensitive to PRL2 inhibition, a result that would be consistent with the additional activity of PRL2 on PTEN such as demonstrated in the current study. The gene discussed is FLT3; the disease is acute myeloid leukemia.